16017-69-9

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 71, p. 4154, 1949 DOI: 10.1021/ja01180a513

InChI:InChI=1/C9H10ClNO2/c1-2-13-9(12)7-4-3-6(11)5-8(7)10/h3-5H,2,11H2,1H3

Upstream product

• 64-17-5 ethanol 
• 38667-55-9 4-Acetylamino-2-chlorobenzoic acid 
• 10369-82-1 2-(diethylamino)ethyl acetate 
• 10367-96-1 2-(diethylamino)ethyl 2-chloro-4-nitrobenzoate 
• 73097-02-6 ethyl 2-chloro-4-nitrobenzoate 
• 141-78-6 ethyl acetate 
• 121-86-8 2-chloro-4-nitrotoluene 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 2457-76-3 4-amino-2-chlorobenzoic acid 

Downstream Products

• 100141-57-9 2-chloro-4-propylamino-benzoic acid ethyl ester 
• 86410-29-9 ethyl 2-chloro-4-(hexadecylamino)benzoate 
• 92712-69-1 ethyl 2-chloro-4-iodobenzoate 
• 100960-18-7 4-amino-2-chlorobenzohydrazide 
• 1057076-54-6 ethyl 4-amino-2-chloro-3-iodobenzoate 
• 1057076-51-3 ethyl 4-amino-2-chloro-5-iodobenzoate 
• 1398050-59-3 N⁵-(1-carbamothioylcyclopropyl)-6-chloro-1-ethyl-N²-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 
• 1398050-65-1 6-chloro-3-cyano-N₅-(1-cyanocyclopropyl)-1-ethyl-N₂-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 
• 1398050-57-1 3,6-dichloro-N⁵-(1-cyanocyclopropyl)-1-ethyl-N²-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 
• 1398050-86-6 6-chloro-N⁵-(1-cyanocyclopropyl)-1-cyclopropyl-N²-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 
• 1398052-40-8 6-chloro-N⁵-(1-cyanocyclopropyl)-N²-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 
• 1398047-76-1 6-chloro-N⁵-(1-cyanocyclopropyl)-1-(prop-2-yn-1-yl)-N²-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,5-dicarboxamide 

Relevant academic research and scientific papers

RETINOID COMPOUND AND PHARMACEUTICAL COMPOSITION

PROBLEM TO BE SOLVED: To provide a novel retinoid compound that is low in teratogenicity, and a pharmaceutical composition containing said retinoid compound. SOLUTION: Provided are a retinoid compound which is a compound represented by the following formula (1) or a salt thereof, and a pharmaceutical composition containing said retinoid compound. In the formula, R1 represents a halogen atom, and R2 and R3 each independently represent a silyl group. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

Design and optimization of N-acylhydrazone pyrimidine derivatives as E. coli PDHc E1 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study

By targeting the thiamin diphosphate (ThDP) binding site of Escherichia coli (E. coli) pyruvate dehydrogenase multienzyme complex E1 (PDHc E1), a series of novel ‘open-chain’ classes of ThDP analogs A, B, and C with N-acylhydrazone moieties was designed and synthesized to explore their activities against E. coli PHDc E1 in vitro and their inhibitory activity against microbial diseases were further evaluated in vivo. As a result, A1–23 exhibited moderate to potent inhibitory activities against E. coli PDHc E1 (IC50 = 0.15–23.55 μM). The potent inhibitors A13, A14, A15, C2, had strong inhibitory activities with IC50 values of 0.60, 0.15, 0.39 and 0.34 μM against E. coli PDHc E1 and with good enzyme-selective inhibition between microorganisms and mammals. Especially, the most powerful inhibitor A14 could 99.37% control Xanthimonas oryzae pv. Oryzae. Furthermore, the binding features of compound A14 within E. coli PDHc E1 were investigated to provide useful insights for the further construction of new inhibitor by molecular docking, site-directed mutagenesis, and enzymatic assays. The results indicated that A14 had most powerful inhibition against E. coli PDHc E1 due to the establishment of stronger interaction with Glu571, Met194, Glu522, Leu264 and Phe602 at active site of E.coli PDHc E1. It could be used as a lead compound for further optimization, and may have potential as a new microbicide.

Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure

The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic heteroaroma

MODULATORS OF MITOTIC KINASES

The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof: (formula should be inserted here) which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.

Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity

Compounds of the formula wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.